Pfizer and Genentech Duke it Out in Court over Herceptin Biosimilar Patents Post author:Sam Post published:November 21, 2017 Post category:BioPharma Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Source: BioSpace You Might Also Like Pfizer Quietly Takes 16.4% Stake in This SoCal Medtech Firm February 13, 2017 Bay Area's Gritstone Oncology to Ramp Up Hiring at New Manufacturing Facility November 27, 2017 Perrigo Unveils Sale of Two Business Units August 10, 2017
